Research statistics
Tesofensine research: publications and trials
At a glance
Publications, all years
39
Since 2001
Publications in 2026 so far
1
Through November 15, 2026
Human clinical research
39.5%
15 of 38 classified
Registered clinical trials
13
ClinicalTrials.gov
Randomized controlled trials
12
Publications reporting an RCT in people
Systematic reviews and meta-analyses
1
Preclinical studies
26.3%
9 animal · 1 in vitro · 0 computational
Records that only mention it
17
Not counted above
Status in the library: In clinical trials. 1 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
- Not a peptide: it is shown for completeness and left out of every peptide total.
Publications by year
Tesofensine publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2001 | 0 | 0 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 0 | 0 | 1 |
| 2006 | 0 | 1 | 0 | 0 | 1 |
| 2007 | 2 | 1 | 0 | 0 | 3 |
| 2008 | 2 | 0 | 1 | 1 | 4 |
| 2009 | 2 | 0 | 2 | 3 | 7 |
| 2010 | 4 | 2 | 1 | 0 | 7 |
| 2011 | 1 | 1 | 1 | 1 | 4 |
| 2012 | 0 | 0 | 1 | 0 | 1 |
| 2013 | 1 | 2 | 0 | 1 | 4 |
| 2018 | 0 | 0 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 0 | 0 | 1 |
| 2024 | 0 | 1 | 0 | 0 | 1 |
| 2025 | 0 | 2 | 0 | 0 | 2 |
| 2026 (to date) | 1 | 0 | 0 | 0 | 1 |
Study types
| Randomized controlled trial | 12 |
|---|---|
| Animal study | 9 |
| Review | 7 |
| Editorial, letter or other | 5 |
| Other clinical trial | 3 |
| In vitro study | 1 |
| Meta-analysis | 1 |
| Not yet classified | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Obesity and weight management | 26 |
|---|---|
| Neurological and mental health | 16 |
| Cognitive health | 4 |
| Cardiovascular | 3 |
| Metabolic health | 2 |
Registered clinical trials
3 of 9 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 11 · Withdrawn: 2
Phase 1: 1 · Phase 1 / Phase 2: 1 · Phase 2: 11
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.
Obesity (Silver Spring, Md.) · March 20, 2008 · Meta-analysis · cited 57 times
PMID 18356831 · DOI 10.1038/oby.2008.56 · Reviews and meta-analyses
- Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.
European journal of endocrinology · May 9, 2022 · Randomized controlled trial · cited 43 times · open access
PMID 35294397 · DOI 10.1530/eje-21-0972 · Human clinical research
- The effect of tesofensine on appetite sensations.
Obesity (Silver Spring, Md.) · June 30, 2011 · Randomized controlled trial · cited 36 times · open access
PMID 21720440 · DOI 10.1038/oby.2011.197 · Human clinical research
- Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.
Clinical pharmacology and therapeutics · June 2, 2010 · Randomized controlled trial · cited 40 times
PMID 20520602 · DOI 10.1038/clpt.2010.67 · Human clinical research
- The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.
International journal of obesity (2005) · May 18, 2010 · Randomized controlled trial · cited 49 times
PMID 20479765 · DOI 10.1038/ijo.2010.87 · Human clinical research
- Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.
The AAPS journal · January 15, 2010 · Randomized controlled trial · cited 10 times · open access
PMID 20077053 · DOI 10.1208/s12248-009-9164-6 · Human clinical research
- [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].
Ugeskrift for laeger · October 1, 2009 · Randomized controlled trial · cited 5 times
PMID 19824222 · Human clinical research
- A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.
Clinical pharmacokinetics · January 1, 2009 · Randomized controlled trial · cited 34 times
PMID 19705923 · DOI 10.2165/11313370-000000000-00000 · Human clinical research
- Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
Lancet (London, England) · October 22, 2008 · Randomized controlled trial · cited 193 times
PMID 18950853 · DOI 10.1016/s0140-6736(08)61525-1 · Human clinical research
- Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.
Archives of neurology · May 1, 2008 · Randomized controlled trial · cited 33 times
PMID 18474731 · DOI 10.1001/archneur.65.5.577 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
Lancet (London, England) · October 22, 2008 · Randomized controlled trial · cited 193 times
PMID 18950853 · DOI 10.1016/s0140-6736(08)61525-1 · Human clinical research
- Centrally Acting Agents for Obesity: Past, Present, and Future.
Drugs · July 1, 2018 · Review · cited 150 times · open access
PMID 30014268 · DOI 10.1007/s40265-018-0946-y · Reviews and meta-analyses
- Serotonergic anti-obesity agents: past experience and future prospects.
Drugs · December 1, 2011 · Review · cited 63 times
PMID 22085383 · DOI 10.2165/11596680-000000000-00000 · Reviews and meta-analyses
- Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.
Obesity (Silver Spring, Md.) · March 20, 2008 · Meta-analysis · cited 57 times
PMID 18356831 · DOI 10.1038/oby.2008.56 · Reviews and meta-analyses
- Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society · February 1, 2007 · Randomized controlled trial · cited 50 times
PMID 17149725 · DOI 10.1002/mds.21258 · Human clinical research
Latest publications
- Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine.
Drug testing and analysis · June 19, 2026 · Other clinical trial · cited 0 times · open access
PMID 42320973 · DOI 10.1002/dta.70104 · Human clinical research
- Structural basis for pharmacotherapeutic action of triple reuptake inhibitors.
Nature communications · December 14, 2025 · In vitro study · cited 6 times · open access
PMID 41392177 · DOI 10.1038/s41467-025-66670-3 · In vitro studies
- Sex-specific effects of appetite suppressants on stereotypy in rats.
PloS one · June 24, 2025 · Animal study · cited 1 times · open access
PMID 40554466 · DOI 10.1371/journal.pone.0325067 · Animal studies
- Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.
PloS one · April 24, 2024 · Animal study · cited 6 times · open access
PMID 38656972 · DOI 10.1371/journal.pone.0300544 · Animal studies
- Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.
European journal of endocrinology · May 9, 2022 · Randomized controlled trial · cited 43 times · open access
PMID 35294397 · DOI 10.1530/eje-21-0972 · Human clinical research
- Centrally Acting Agents for Obesity: Past, Present, and Future.
Drugs · July 1, 2018 · Review · cited 150 times · open access
PMID 30014268 · DOI 10.1007/s40265-018-0946-y · Reviews and meta-analyses
- Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · October 22, 2013 · Other clinical trial · cited 36 times
PMID 24239329 · DOI 10.1016/j.euroneuro.2013.10.007 · Human clinical research
- Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat.
Pharmacology, biochemistry, and behavior · August 7, 2013 · Animal study · cited 33 times
PMID 23932919 · DOI 10.1016/j.pbb.2013.07.018 · Animal studies
- Under-reporting of adverse effects of tesofensine.
Lancet (London, England) · July 1, 2013 · Editorial, letter or other · cited 9 times
PMID 23849924 · DOI 10.1016/s0140-6736(13)61563-9 · Commentary and other
- Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats.
Obesity (Silver Spring, Md.) · May 1, 2013 · Animal study · cited 22 times · open access
PMID 23784901 · DOI 10.1002/oby.20122 · Animal studies
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: NS2330; Tesofensine; TESOFENSINUM
((TITLE_ABS:"NS2330" OR CHEM:"NS2330" OR TITLE_ABS:"NS 2330" OR CHEM:"NS 2330") OR (TITLE_ABS:"Tesofensine" OR CHEM:"Tesofensine") OR (TITLE_ABS:"TESOFENSINUM" OR CHEM:"TESOFENSINUM")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Tesofensine research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/tesofensine